ADR (QNRX) stock price has shown some volatility, fluctuating -40.30% over the last five trades and -34.67% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...

In a turbulent market environment, QNRX stock has reached a new 52-week low, trading at just $0.42. According to InvestingPro data, while the company maintains a FAIR financial health score and holds ...

U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations Quoin Pharmaceuticals (NASDAQ:QNRX ...

ADR (QNRX) stock price has shown some volatility, fluctuating -35.40% over the last five trades and -33.06% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) and keeping the price target at ...

Quoin Pharmaceuticals (QNRX) announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome. In December 2024 ...

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92.

Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.

ASHBURN, Va. - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company with a market capitalization of $2.89 million, announced positive interim clinical data ...